cardiac rehabilitation fish oil kidney disease polyunsaturated fatty acids ■ PURPOSE: The correlation between chronic kidney disease (CKD) and increased cardiovascular disease-related mortality is well established. Cardiac rehabilitation (CR) improves exercise capacity, quality of life, and risk factors in patients with coronary artery disease (CAD). Data on the benefits of CR in patients with CKD are sparse. The purpose of this study was to compare outcomes after CR in patients with CAD but normal renal function, versus those with CAD and CKD.
skeletal muscle are deranged, [5] [6] [7] which may be exacerbated by the associated metabolic acidosis. 5 In addition, energy production by mitochondria is also reduced in CKD. [8] [9] [10] [11] [12] [13] [14] Despite these physical derangements, exercise capacity may be improved in such patients. 15 , 16 Cardiac rehabilitation (CR) improves exercise capacity and outcomes among patients with coronary artery disease (CAD), 17 but studies of the effect of CR on patients with coexisting CKD are sparse. 18 The aim of this study was therefore to compare the outcomes after CR in patients with CAD and normal renal function with those of patients with both CAD and CKD.
Polyunsaturated fatty acids (PUFAs) have been reported to improve exercise capacity in patients with cardiovascular disease and chronic obstructive pulmonary disease. 19 , 20 There have also been some suggested benefits of PUFA in patients with CKD. 21 , 22 Therefore, the use of fish oil during CR was assessed to identify any effect on outcomes in our patients.
METHODS
Between 2004 and 2012, 804 patients were enrolled in an outpatient CR program at Wake Forest Baptist Medical Center. Serum creatinine levels were measured within 30 days before they began CR. The Wake Forest Baptist Medical Center Institutional Review Board approved the use of patients' medical records to collect clinical data.
CR patients had undergone interventions for CAD, including cardiac catheterization, percutaneous coronary intervention, and/or coronary artery bypass surgery. Glomerular filtration rate (GFR) was estimated using the isotope dilution mass spectrometry-traceable Modification of Diet in Renal Disease (MDRD) Study method and collected within 30 days before the start of CR and within 30 days after the last CR session. The (Stage IV-V CKD and/or on dialysis, n = 22, 16 of whom were dialysis patients). CKD stages were defined according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) 24 ( Figure ) . The diagnosis of Stage I CKD (GFR > 90 mL/min/1.73 m 2 ) and Stage II CKD (GFR 60-89 mL/min/1.73 m 2 ) requires urine findings, structural abnormalities, or presence of genetic traits suggestive of kidney disease; these factors were not assessed during this study. For simplicity, patients with a GFR ≥ 60 mL/min/1.73 m 2 are referred to as non-CKD patients, although these patients could have Stage I or Stage II CKD.
Details of our CR program have been previously reported. 25 It lasted 12 weeks (three 30-to 40-minute sessions per week of upper and lower body exercises with exercise machines). Clinical status was used by an exercise physiologist to develop an individualized exercise plan. 26 At each visit, vital signs were recorded before each session, including height, weight, systolic and diastolic pressures, and heart rate. In our program, exercise comprises upper and lower body training methods including walking laps on a track, cycle ergometry, treadmills, and stair climbers. The emphasis is on a mixture of modes of aerobic exercise although light resistance exercises using elastic bands are used at the end of each session.
Metabolic equivalent (MET) levels were recorded at each session and obtained either automatically from exercise devices or using a standardized and validated MET formula from the American College of Sports Medicine 27 during the aerobic phase of exercise after the participants were roughly half-way through each session. The goal is to increase exercise over the previous session as tolerated to a rating of perceived exertion of 11 to 14 on a 6-to 20-point Borg scale. 27 The MET level for that, and each subsequent visit was the greatest level of exertion for the patient for that visit. The MET level at the first visit was the baseline. We noted the highest MET level attained at any time after baseline measurement. The difference between this and the baseline level is the change, and this is what we report in the various groups. In this manner, we were able to track temporal escalation of sessional MET levels as the patients advanced through the program.
Hypertension was defined according to the guidelines JNC 7. 28 Baseline blood pressure was defined as the first measurement taken, and the postblood pressure was the last measurement for each patient. The Ferrans and Powers Quality of Life Index 29 was determined by questionnaires. This validated instrument 30 tests overall quality of life, health and functioning, psychological well-being, social and economic satisfaction, and family contentment. It was administered routinely by nursing staff in our program. Quality-oflife scores were calculated before and after CR. Left ventricular function was measured by standard techniques. 31 Lipid goals were defined in accordance with the Adult Treatment Panel III guidelines. 32 The use of fish oil (PUFA) by each patient was determined by medical record review.
Statistical Analysis
Descriptive statistics (frequency and percentage for categorical variables, mean and standard deviation for continuous variables) were calculated and compared at baseline for statistical significance using χ 2 or Fisher exact tests for categorical variables and t tests for continuous variables. For baseline statistics we used standard deviations, and for absolute differences we used 95% CI. Absolute changes were calculated as mean (95% CI) of postrehabilitation minus baseline levels, and compared using analysis of variance with F-testing. We evaluated all patient demographic and clinical variables from Table 1 for the multivariate models. The dependent variable was absolute change in METs from baseline accounting for baseline differences between the groups. Multivariable linear regression models were constructed with increase in METs from baseline as the dependent variable. Independent predictors were selected for inclusion using a backward selection methodology. All potentially significant univariate predictors of exercise capacity ( P < .10) were included in the model, and the least significant covariates were removed individually until all remaining covariates were statistically significant predictors of exercise capacity. Two-and 3-way interaction terms between independent predictors in the final models were further tested for statistical significance. A P value of ≤ .05 was considered statistically significant. The SAS version 9.3 statistical software package (SAS Institute, Cary, NC) was used for all statistical analyses.
RESULTS
Baseline patient demographics and clinical characteristics by GFR are shown in Table 1 . Compared with patients with a GFR ≥ 60 mL/min/1.73 m 2 , those with a GFR < 60 were more likely to be of nonwhite race and had a lower body mass index ( P < .05 for both). A GFR < 60 mL/min/1.73 m 2 was also associated with higher prevalence of diabetes, more single-vessel disease, lower quality of life, and lower exercise capacity ( P < .05 for all). PUFAs were used by approximately 25% of all patients, regardless of GFR ( P > .05).
After CR, all patients saw statistically significant improvements in exercise capacity, quality of life, and weight, regardless of baseline GFR. Patients with a GFR ≥ 60 mL/min/1.73 m 2 had significant improvements in all usual CR metrics ( Table 2 ). Increase in exercise capacity was greatest in patients with a baseline GFR ≥ 60 mL/min/1.73 m 2 . Significant correlation between the baseline MET and both the change and highest MET was found (Spearman coefficient r = 0.22, and r = 0.69, P < 0.001 for both). Patients with a GFR < 60 mL/min/1.73 m 2 also saw significant improvements, albeit to a lesser degree. Patients with a GFR ≥ 60 mL/min/1.73 m 2 had the greatest improvement in low-density lipoprotein (LDL); patients with a GFR < 30 mL/min/1.73 m 2 showed little to no improvement in LDL. High-density lipoprotein (HDL) improved in patients with a GFR ≥ 60 mL/min/1.73 m 2 and in those with a GFR 30 to 59 mL/min/1.73 m 2 , but not in those with a GFR < 30 mL/min/1.73 m 2 . Among patients with a GFR ≥ 60 mL/min/1.73 m 2 and in those with a GFR 30 to 59 mL/min/1.73 m 2 , PUFA use was associated with a statistically significant increase in MET level compared with nonusers ( Table 3 ). In addition, in those with a GFR 30 to 59 mL/min/1.73 m 2 greater weight loss occurred among PUFA users compared with non-users ( Δ 4.0 vs Δ 1.5, Figure ) . There were insufficient data in patients with a GFR < 30 mL/min/1.73 m 2 to assess any effects of PUFA use.
Following multivariable adjustment, a GFR 30 to 59 mL/min/1.73 m 2 was independently associated with decreased improvement in MET levels relative to a GFR ≥ 60 mL/min/1.73 m 2 ( β = − 0.39), while controlling for other covariates in the model. In addition to decreased GFR, increased age, female sex, increased baseline body mass index, and ejection fraction < 35%
www.jcrpjournal.com were significant independent predictors of decreased exercise capacity. Baseline MET, PUFA use, and total number of CR sessions attended were significant independent predictors of increased exercise capacity. The details of the multivariate analysis of change in exercise capacity are shown in Table 4 . www.jcrpjournal.com
T a b l e 2 • Metrics After Cardiac Rehabilitation by Baseline Renal Function
The outcomes, which we have included in our results, are shown with those of previous studies for comparison in Table 5 .
DISCUSSION
The literature on CR in patients with CKD remains sparse, and data are difficult to compare because of population differences and varying endpoints. 18 , 33 , 34 In our patients, we found that CKD was common. Furthermore, CKD negatively impacted the improvement in exercise capacity in patients with CAD, but this could be partially mitigated by the use of PUFA.
In a previous study, Venkataraman et al 18 reported on 115 patients with CKD undergoing CR; however, weight, diastolic blood pressures, statin usage, effects on renal function, and outcomes in dialysis patients were not reported. In a recent registry-based study from Germany, Völler et al 34 described outcomes in more than 35 000 patients with CKD who had undergone CR. These patients were older (mean age 72 years) and 97% had undergone a 3-week in-hospital CR program. Takaya et al 33 reported the effects of a 3-month outpatient-based CR program on renal function. There were notable baseline differences compared with other studies: the mean body mass index of the patients in the Japanese study was 22.9 (compared with 26 in Germany, 34 30 in the year 2005 in Alabama, 18 and 28 in our current study). In addition, in the Japanese study, 70% were smokers, 5 to 10 times greater than other studies. These authors did not report the effects of CR on risk factors. The effects of CR on risk factors and GFR in these studies are displayed in Table 5 (findings in our study are also shown for ease of comparison). Some of the differences may be due to differences in practice guidelines and/or program duration. For example, in our study, between 80% and 90% of our patients were taking a statin, whereas Venkataraman et al 18 did not report data on statin usage, and in Germany, the CR program usually lasted only 3 weeks. 34 In common with the other studies of CR, 18 , 33 , 34 and with observations of CKD in general, 35 , 36 our patients began at a lower exercise capacity than those with normal renal function. Venkataraman et al 18 used a 6-minute walk and showed an improvement in exercise capacity with CR in patients with CKD, similar to that of Völler et al. 34 Takaya et al 33 demonstrated an increase in V . O 2 using cycle ergometry. In our patients with Stage III CKD, using estimated MET levels, exercise capacity also increased and, although this improvement was less than in patients with no CKD, may have been further enhanced by the use of PUFA although the mechanism(s) are unclear. Decreased exercise capacity in patients with CKD is multifactorial. Skeletal muscular dysfunction plays an important role, [37] [38] [39] and dysfunction of mitochondria, the primary source for energy production, may contribute. 9-11 , 13 , 40 Increased exercise capacity in PUFA users with chronic obstructive lung disease and nonischemic cardiomyopathy 19 , 20 may be due to improved muscle metabolism 20 and/or mitochondrial synthesis and function. [41] [42] [43] Regardless of the mechanism, the findings are consistent with a beneficial effect of PUFA use on exercise capacity in patients with CKD, 21 , 22 , 44 an area of active investigation in this patient group. 45 In previous studies, 18 , 33 , 34 no data on patients on dialysis were reported. We found no outcome differences between patients with a GFR less than 30 (not on dialysis) and those on dialysis and merged their data in statistical analyses, and so included them together. Despite other improvements, we found no significant change in LDL, HDL, triglycerides, or blood pressure after CR. We could not assess the effect of PUFA in the dialysis group as only 3 patients were users.
T a b l e 4 • Multivariate Predictors of Significant Change in METs From Baseline
Limitations of the current study are that it was at a single site and retrospective with possible inherent selection bias especially for PUFA use. Serial creatinine levels were not recorded, so we could not document sustained renal impairment for a minimum of 3 months, the criterion for CKD according to the NKF KDOQI. 24 Renal pathology, renal imaging, or proteinuria was not evaluated to identify patients with a GFR ≥ 60 mL/min/1.73 m 2 with Stage I or Stage II CKD. Differences between normal estimated GFR and patients with CKD included an increase of 8 years in mean age and higher proportion of women (33% vs 24%) in patients with CKD although the main findings remained robust after adjustment in multivariate analysis. PUFA use during CR was determined by medical records review and is given here as a dichotomous variable as details of dose and type of pharmaceutical preparation were not available in all patients. Reported MET levels were calculated from moderate-intensity exercises without more precise formal stress or metabolic testing. In addition, the same exercise device was not used for each patient for each MET level. However, our previously reported investigations without stress tests 25 , 46 concur qualitatively with other studies using formal treadmill exercise testing. 47 , 48 Finally, we did not evaluate muscle function, which may be adversely affected in patients with CKD. CR nevertheless benefits patients with CKD, even in those receiving dialysis, enhancing exercise capacity and improving weight. Furthermore, these effects may be enhanced by the adjunctive use of PUFA. The hypothesis generated by our data should be formally tested, avoiding these shortcomings, in well-designed prospective, randomized clinical trials. 
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